Partial
Mostly Aligned
Patient Risk:
Low
Summary
The AI-generated claims primarily address patient assistance programs not described in the Vascepa label. Only the statement that Vascepa contains icosapent ethyl is supported by the prescribing information; the remaining claims have no label support.
Category Scores
Accurate Statements
Vascepa contains icosapent ethyl.
Description; How Supplied/Storage and Handling
Unsupported Statements
Doctors typically do not provide Vascepa patient assistance forms directly.
Not described in prescribing information.
The patient assistance forms are issued by the manufacturer, Amarin Pharma.
Not described in prescribing information.
They are issued through the Vascepa Savings Program or patient assistance programs like the AmarinCARE Foundation.
Not described in prescribing information.
Patients or providers must request them online or by phone from the program's website or hotline.
Not described in prescribing information.
To obtain enrollment forms, visit the official Vascepa savings site (vascepasavings.com) or call 1-877-304-3188 to download enrollment forms or request them by mail.
Not described in prescribing information.
Eligibility often requires proof of income and lack of insurance coverage for the drug (icosapent ethyl).
Not described in prescribing information.
Some pharmacies or clinic staff can assist with submission, but the forms originate from Amarin.
Not described in prescribing information.
Doctors can guide you on eligibility, complete the prescriber section of the form after you obtain it, or refer you to the program.
Not described in prescribing information.
They might also prescribe Vascepa and note assistance needs on the script, but they lack authority to generate or distribute the official forms themselves.
Not described in prescribing information.
Uninsured or underinsured patients earning up to 400-500% of the federal poverty level (around $60,000-$75,000 for an individual in 2024) often qualify for free or discounted supply (up to 12 months).
Not described in prescribing information.
Commercial insurance patients may get copay cards reducing out-of-pocket costs to $9 per month.
Not described in prescribing information.
A 30-day supply (120 capsules) lists at $300-$400 retail without insurance or coupons.
Not described in prescribing information.
Assistance can make it free.
Not described in prescribing information.
Generics are not yet available due to ongoing patents expiring in 2028-2031.
Not described in prescribing information.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The claims concern patient assistance programs rather than safety or medical risk.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Most claims pertain to non-labeled patient assistance programs; only the active ingredient statement is label-supported.
Suggested Improvement
Limit claims to label-supported content; clearly separate non-label information about patient assistance programs from label-based content.